Failed drug trials
We’re disappointed that Biogen AND Eisai have stopped two phase III trials of Alzheimer’s drug aducanumab. But we’re encouraged by the growing number of new avenues being explored by researchers across the world. Their work has never been more important.
We’re hearing in the news that a new treatment designed to slow Alzheimer’s has shown benefit in one of the final stages of testing in people. So what’s going on?
The report shines a necessary spotlight on some of the challenges facing dementia research today.
One year since the G8 Dementia Summit, new investment and exciting initiatives are bringing us closer to a treatment for dementia.
We need to learn from recent failings in clinical trials and inform research feeding back into the early drug development pipeline.
We look at the most promising developments in the treatments of Alzheimer’s disease.
Alzheimer’s Research UK’s Director of Research Dr Eric Karran spoke recently about his hopes for the development of new Alzheimer’s treatments and dementia research.
The latest results from the Elan dementia trials have proved one of the more interesting dementia research stories of the summer.
This month we’ll be at the political party conferences urging all parties to continue to back dementia research. With no new drugs since 2003, and those in existence only showing modest efficacy, we desperately need new treatments that can delay the onset, slow the progression and manage the symptoms of dementia.